Editorial

ADC Therapeutics and Genmab Agree to Develop Antibody-drug Conjugate

Earlier this week Swiss-based oncology drug development company ADC Therapeutics Sarl and Danish Genmab A/S agreed to develop a...

From the Editors: Welcome to a New Publication – ADC Review/Journal of Antibody-drug Conjugates

Welcome to ADC Review, Journal of Antibody-Drug Conjugates, a new online, peer-reviewed, open-access hybrid publication for those involved in...

Clinical Trial with Inotuzumab Ozogamicin in Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma (NHL) Discontinued...

Earlier today, Pfizer Inc. confirmed that it had discontinued a Phase III randomized, open-label, two-arm study (B1931008) evaluating the...

Women with Highest Expression of Target Protein Benefited Most of Experimental Drug Active in...

The antibody-drug conjugate DMUC5754A, a novel trial drug of a relatively new class of agents developed by Genentech, a...

Second Generation HER2-antibody-drug conjugate Offers Best-in-Class Potential and Improved Therapeutic Index

In pre-clinical xenograft studies using patient-derived breast cancer and non-small-cell lung cancer material, Synthon Biopharmaceuticals, a subsidiary of specialty...

New CD33-Directed Antibody-Drug Conjugate, Utilizing Pyrrolobenzodiazepine Dimers, Demonstrates Anti-tumor Activity in Multi-Drug Resistant Human...

Preclinical data from SGN-CD33A (Seattle Genetics, Inc), a novel CD33-directed antibody-drug conjugate (ADC) in development for the treatment of acute...

The Next Advancements in Cancer Drug Development: Antibody-Drug Conjugates

The annual meeting of the American Society of Clinical Oncology (ASCO) conference held June 1-5, 2012 in Chicago, IL...

Linker Stability Enhances Efficacy of Antibody-SN-38

Results from ongoing studies of two bispecific, hexavalent, antibodies, 1R-(E1)-(E1) and 1R-(15)-(15), for treating breast, pancreatic and other solid...

Monoclonal Antibodies (mAbs), the “Magic Bullets” of Cancer Care, Are Now Fulfilling their Promise

Monoclonal Antibodies (mAbs), once touted as the "magic bullets" of cancer care, are now fulfilling that promise and more...

Phase III Front-line Trial Planned with Brentuximab Vedotin in Advanced Stage Hodgkin Lymphoma Patients

Interim results from a phase I clinical trial of brentuximab vedotin(SGN-35, Adcetris™, Seattle Genetics/Millennium: The Takeda Oncology Company) in...